Spleen-targeted delivery systems and strategies for spleen-related diseases

• DOI: 10.1016/j.jconrel.2024.05.007
• Publication Date: 2024-05-17T21:00:45Z
• Authors: Ziyao Huang; Kedong Sun; Zhenyu Luo; Junlei Zhang; Huanli Zhou; Hang Yin; Zhile Liang; Jian You
• Keywords: Drug Delivery Systems; Humans; Animals; Nanoparticles; Spleen; Splenic Diseases

The spleen, body's largest secondary lymphoid organ, is also a vital hematopoietic and immunological organ. It is regarded as one of the most significant organs in humans. As more researchers recognize the functions of the spleen, clinical methods for treating splenic diseases and spleen-targeted drug delivery systems to improve the efficacy of spleen-related therapies have gradually developed. Many modification strategies (size, charge, ligand, protein corona) and hitchhiking strategies (erythrocytes, neutrophils) of nanoparticles (NPs) have shown a significant increase in spleen targeting efficiency. However, most of the targeted drug therapy strategies for the spleen are to enhance or inhibit the immune function of the spleen to achieve therapeutic effects, and there are few studies on spleen-related diseases. In this review, we not only provide a detailed summary of the design rules for spleen-targeted drug delivery systems in recent years, but also introduce common spleen diseases (splenic tumors, splenic injuries, and splenomegaly) with the hopes of generating more ideas for future spleen research.